Merck, CAR T, and Biotech Access
Kilder
- Endpoints: Merck plans trial of sac-TMT combo with Keytruda in lung cancer
- Labiotech: Eight CAR-T companies tackling autoimmune disorders
- STAT: STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
- STAT: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug - STAT
- STAT: STAT+: Three biotechs with three news updates
- STAT: STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
- STAT: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug - STAT
- STAT: STAT+: Three biotechs with three news updates
- Endpoints: The China Debate: Biotech deserves a deeper discussion
- Labiotech: Cryopreservation in cell therapy: Reducing variability from the start
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.